Who makes ropivacaine 0,375%?

ropivacaine 0,375% is developed by Salzburger Landeskliniken.

What development phase is ropivacaine 0,375% in?

ropivacaine 0,375% is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

ropivacaine 0,375%

Salzburger Landeskliniken · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	ropivacaine 0,375%
Sponsor	Salzburger Landeskliniken
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ropivacaine 0,375% CI brief — competitive landscape report
ropivacaine 0,375% updates RSS · CI watch RSS
Salzburger Landeskliniken portfolio CI